BSE filing, BSE: 543828. Summary written from the filing by ALFA Finder's alert engine.
Sudarshan Pharma Industries Ltd: key numbers
- Share price
- ₹38.00
- Market cap
- ₹914.5 Cr
- Revenue (annual)
- ₹703.1 Cr
- Net profit (annual)
- ₹23.30 Cr
- P/E (TTM)
- 39.2×Sector 34.5×
- Promoter holding
- 57.81%-1.12% QoQ
- FII holding
- 21.94%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sudarshan Pharma Industries Ltd
All →Sudarshan Pharma Industries Board Meeting Date
Sudarshan Pharma's board meets 29 October 2026 to consider Q2 results and a fund-raising proposal. Trading window remains closed until 48 hours after results.
Sudarshan Pharma Industries SME to Main Board Migration
Sudarshan Pharma's shares will list on NSE's main board from October 27, 2026, migrating from BSE SME. Trading begins under symbol SUDARSHAN, marking a platform upgrade.
Sudarshan Pharma Industries Other Announcement
Sudarshan Pharma Industries Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Sudarshan Pharma Industries Merger & Restructuring
Sudarshan Pharma terminated its proposal to acquire 9.50% of Med Therapy Biotechnology Inc. The promoters' parallel 1.50% each acquisition plan also stands terminated.
Sudarshan Pharma Industries Merger & Restructuring Worth ₹1.4 Cr
Sudarshan Pharma Industries completed the sale of its 51% stake in subsidiary Ishwari Healthcare Private Limited for ₹1.40 Crore. The entity ceases to be a subsidiary.
- Value
- ₹1.40 Cr
Sudarshan Pharma Industries Annual General Meeting
Sudarshan Pharma Industries Ltd held its 18th Annual General Meeting on September 22, 2026. The meeting covered the adoption of financial statements and director re-appointment.
Other acquisition announcements
All →Emkay Global Financial Services Acquisition Worth ₹21.38 Cr
Emkay Capital, a subsidiary, will acquire Emkay Investment Managers for Rs.21.38 Crore cash. The related-party deal is at arm's length and payable in tranches.
- Value
- ₹21.38 Cr
- Execution
- 90 days
TVS Motor Company Acquisition Worth ₹25,000 Cr
TVS Motor will acquire 100% of Harita ARC Limited, a related-party shell, for a stated Rs 25,000 Crore. It supports the proposed consumer finance demerger.
- Value
- ₹25,000 Cr
Rite Zone Chemcon India Acquisition Worth ₹4.97 Cr
Rite Zone Chemcon's board approved acquiring 51% of Cleanux Green Solution via share swap for about INR 4.97 Crore. The board also approved preferential issues and an EGM on 23 November 2026.
- Value
- ₹4.97 Cr
eClerx Services Acquisition Worth ₹15.57 Cr
eClerx's board approved buying about 2% of Personiv Eclipse Inc. from its wholly owned subsidiary eClerx LLC for USD 1.64 million. The intra-group transfer adds no change to aggregate ownership.
- Value
- ₹15.57 Cr
- Execution
- 1 Month
Fortis Healthcare Acquisition Worth ₹277 Cr
Fortis Healthcare's wholly-owned subsidiary IHL acquired Suguna Hospital's business and land in Bengaluru via slump sale. The cumulative consideration is approximately INR 277 Crore, consummated today.
- Value
- ₹277.0 Cr
Authum Investment & Infrastructure Acquisition
NCLT approved the consortium resolution plan for A A Estates Private Limited, with Authum as a resolution applicant. No consideration amount is disclosed.